Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adverse biomarkers.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Emili Montserrat, Peter Dreger Tags: SOHO Supplement 2016 Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants